We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Amgen’s Lumakras as First Treatment for Lung Cancer with KRAS Mutation
FDA Approves Amgen’s Lumakras as First Treatment for Lung Cancer with KRAS Mutation
Amgen’s potential blockbuster cancer drug Lumakras (sotorasib) has secured the FDA’s approval for the treatment of adults with nonsmall-cell lung cancer (NSCLCs) whose tumors contain the KRAS G12C gene mutation and who have received at least one prior line of therapy.